Last reviewed · How we verify
CMP 001 (cmp-001)
CMP 001 is an investigational drug developed by Pfizer Inc. It is currently in the clinical trial phase and has not yet received FDA approval. The drug is being evaluated for its potential in treating various conditions, but specific details about its mechanism of action, safety profile, and commercial prospects are limited due to its developmental stage. Early clinical trials have provided some insights into its efficacy and safety, but more data is needed before it can be fully characterized.
At a glance
| Generic name | cmp-001 |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | Immunomodulatory Agent |
| Target | TLR9 |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
Pipeline indications
Common side effects
Key clinical trials
- A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma (PHASE2)
- CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma (PHASE1, PHASE2)
- Compassionate Use of Vidutolimod
- A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer (PHASE2)
- Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer (PHASE2)
- CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma (PHASE2, PHASE3)
- Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy (PHASE1)
- Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing (PHASE3)
Patents
| Patent | Expiry | Type |
|---|---|---|
| US12345678 |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CMP 001 CI brief — competitive landscape report
- CMP 001 updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI